Module 2: Practical Nonclinical Considerations for Developing Autologous and Allogeneic Cell Therapies

Recorded On: 03/16/2023

image
image


There has been a rapid growth of cell therapy approaches over the past several years, resulting in product approvals providing substantial advancements in the treatments of serious diseases particularly in oncology. Cell-based therapies are the transfer of intact, live cells into a patient with the goal of preventing, treating, or curing a disease or condition. The source of the cells may come from the patient who will also be the recipient, in which case the source is termed autologous, or the cells may be obtained from a donor, in which case the source is termed allogeneic. These cells may be modified through gene-editing, treatment with cytokines, and/or other novel techniques. Generally, cell therapies use case-by-case approaches as they advance through the product development and regulatory interactions to the clinic, and eventually the marketplace. This session will address the overarching nonclinical challenges as well the more practical challenges of program and study execution. In addition, how interactions with regulators can help address these challenges will be discussed.

Mary Ellen Cosenza, PhD, MS, DABT, ATS, ERT, RAC

Mary Ellen Cosenza, PhD, MS, DABT, ATS, ERT, RAC

Consultant

MEC Regulatory and Toxicology Consulting

Dr. Mary Ellen Cosenza is a regulatory consultant with over 30 years of senior leadership experience in the biopharmaceutical industry in the US, Europe, and emerging markets. During her 20-year tenure at Amgen, she led the US Regulatory Department, the International Emerging Markets Regulatory Department, and served as an Executive Director of Global Regulatory Affairs and Safety, focusing on Early Development, Medical Writing, and Inflammation. In addition to her leadership roles in Regulatory Affairs, she also served as the Senior Director of Toxicology at Amgen. Prior to joining Amgen, she served as a Principal Scientist in Toxicology for the Medical Research Division of American Cyanamid Company (now Pfizer).  

While at Amgen, Dr. Cosenza was responsible for both early- and late-stage development programs resulting in numerous successful IND, CTA, NDA, MAA, and BLA submissions in a wide variety of therapeutic areas and modalities. In addition, she played a key leadership role in preparing teams for global health authority meetings with FDA, EMA, and regional country health authorities, including several FDA Advisory Committee Meetings.

Dr. Cosenza is recognized as an expert in preclinical biologic drug development and is a founding member of BIO’s BioSafe Preclinical Expert group. She was also a member of an Expert Working Group, operating under the auspices of the International Conference on Harmonization (ICH) for ICH M3(R2). Dr. Cosenza is well-published in the field of biological drug development, has authored several chapters on this topic, and recently co-edited a book on Translation Sciences focused on biologics and innovative products such as cell and gene therapies. She was also a co-editor of a Toxicological Pathology book for non-pathologists.

Dr. Cosenza is a Diplomat of the American Board of Toxicology, a Fellow of the Academy of Toxicological Sciences (current President), a member of the Society of Toxicology (SOT), Drug Information Association (DIA), and the Regulatory Affairs Professional Society (RAPS), and holds Regulatory Affairs Certification for both the US and EU. Dr. Cosenza is a European Registered Toxicologist (ERT) via the Royal Society of Biology, UK. She is also Treasurer of the International Union of Toxicology (IUTOX). Dr. Cosenza is a member of the American College of Toxicology (ACT), where she has served as a member of the ACT Education Committee, as Councilor, and as Treasurer and then President. She is an adjunct at the University of Southern California, where she teaches a graduate-level course on Food and Drug Toxicology and undergraduate classes on drug development and toxicology.

Dr. Cosenza received her PhD from St. John’s University, New York, and her MS in Regulatory Science from the University of Southern California, Los Angeles.

Key:

Complete
Failed
Available
Locked
Module 2: Practical Nonclinical Considerations for Developing Autologous and Allogeneic Cell Therapies
Module 2: Practical Nonclinical Considerations for Developing Autologous and Allogeneic Cell Therapies, Mary Ellen Cosenza, PhD, MS, DABT, ATS, ERT, RAC
Recorded 03/16/2023  |  90 minutes
Recorded 03/16/2023  |  90 minutes As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Survey
13 Questions
13 Questions ACT values your feedback. Please help us continue to provide high-quality educational offerings by completing this short survey. The survey will become available after you have met the minimum viewing requirement for the recording. Once you complete the survey, your certificate of completion will become available on your dashboard or for download.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Your certificate of completion will become available after you have met the minimum viewing requirement and completed the module survey.